Risk factors for cardiac implantable electronic device infection: A systematic review and meta-analysis

Europace

Volumn 17, Issue 5, 2015, Pages 767-777

  Polyzos, Konstantinos A ^a,b   Konstantelias, Athanasios A ^a   Falagas, Matthew E ^a,c,d  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b KAROLINSKA INSTITUTE   (Sweden)

^c IASO   (Greece)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Defibrillator; Infection; Pacemaker; Predictors; Resynchronization; Risk factors

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; CORTICOSTEROID; ANTIINFECTIVE AGENT;

ANTIBIOTIC PROPHYLAXIS; CARDIAC RESYNCHRONIZATION THERAPY DEVICE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFIDENCE INTERVAL; DATA BASE; DEVICE INFECTION; DIABETES MELLITUS; DRUG USE; END STAGE RENAL DISEASE; EPICARDIUM; FEVER; HEART FAILURE; HEMATOMA; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; INFECTION CONTROL; KIDNEY FAILURE; MEDLINE; META ANALYSIS; OPERATION DURATION; OPERATOR; PACEMAKER IMPLANTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; ADVERSE EFFECTS; AGED; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; COMORBIDITY; DEVICES; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED; ODDS RATIO; PROSTHESIS-RELATED INFECTIONS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIAC RESYNCHRONIZATION THERAPY DEVICES; COMORBIDITY; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSTHESIS-RELATED INFECTIONS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84929250018     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euv053     Document Type: Review

References (91)

1. Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol 2006;48:590-1.
2. Greenspon AJ, Patel JD, Lau E, Ochoa JA, Frisch DR,HoRTet al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol 2011;58:1001-6.
3. Baman TS, Gupta SK, Valle JA, Yamada E. Risk factors for mortality in patients with cardiac device-related infection. Circ Arrhythm Electrophysiol 2009;2:129-34.
4. Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, HayesDLet al. Clinical predictors of cardiovascular implantable electronic device-related infective endocarditis. Pacing Clin Electrophysiol 2011;34:450-9.
5. Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med 2011;171:1821-8.
6. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, WilsonWRet al. Management and outcome of permanent pacemaker and implantable cardioverterdefibrillator infections. J Am Coll Cardiol 2007;49:1851-9.
7. Tarakji KG, Chan EJ, Cantillon DJ, Doonan AL, Hu T, Schmitt S et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm 2010;7:1043-7.
8. Bongiorni MG, Marinskis G, Lip GY, Svendsen JH, Dobreanu D, Blomström-Lundqvist M et al. How European centres diagnose, treat, and prevent CIED infections: results of an European Heart Rhythm Association survey. Europace 2012;14: 1666-9.
9. Kuehn C, Graf K, HeuerW, Hilfiker A, Chaberny IF, StieschMet al. Economic implications of infections of implantable cardiac devices in a single institution. Eur J Cardiothorac Surg 2010;37:875-9.
10. Da Costa A, Kirkorian G, Cucherat M, Delahaye F, Chevalier P, CerisierA et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. Circulation 1998;97:1796-801.
11. Bloom H, Heeke B, Leon A, Mera F, Delurgio D, Beshai J et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol 2006;29:142-5.
12. Spinler SA, Nawarskas JJ, Foote EF, Sabapathi D, Connors JE, Marchlinski FE. Clinical presentation and analysis of risk factors for infectious complications of implantable cardioverter-defibrillator implantations at a university medical center. Clin Infect Dis 1998;26:1111-6.
13. Wiegand UK, LeJeune D, Boguschewski F, Bonnemeier H, Eberhardt F, SchunkertH et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/ anticoagulation therapy. Chest 2004;126:1177-86.
14. Margey R, McCann H, Blake G, Keelan E, Galvin J, LynchMet al. Contemporary management of and outcomes from cardiac device related infections. Europace 2010;12: 64-70.
15. Sohail MR, Hussain S, Le KY, Dib C, Lohse CM, Friedman PA et al. Risk factors associated with early- versus late-onset implantable cardioverter-defibrillator infections. J Interv Card Electrophysiol 2011;31:171-83.
16. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, WilsonWRet al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis 2007;45:166-73.
17. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB et al. Updateoncardiovascularimplantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010; 121:458-77.
18. Silvetti MS, Drago F, Marcora S, Rava L. Outcome of single-chamber, ventricular pacemakers with transvenous leads implanted in children. Europace 2007;9:894-9.
19. Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a populationbased study. Arch Intern Med 2007;167:669-75.
20. DurackDT, Lukes AS, BrightDK.Newcriteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. Am J Med 1994;96:200-9.
21. Choo MH, HolmesDRJr, Gersh BJ, Maloney JD, Merideth J, Pluth JR et al. Permanent pacemaker infections: characterization and management. Am J Cardiol 1981;48: 559-64.
22. Chamis AL, Peterson GE, Cabell CH, Corey GR, Sorrentino RA, Greenfield RA et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001;104:1029-33.
23. Borenstein M, Hedges L, Higgins J, Rothstein H. Comprehensive Meta-analysis, Version 2. Englewood, NJ: Biostat, 2005.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7: 177-88.
25. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
26. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
27. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-63.
28. Bluhm G, Jacobson B, Julander I, Levander-Lindgren M, Olin C. Antibiotic prophylaxis in pacemaker surgery-a prospective study. Scand J Thorac Cardiovasc Surg 1984;18:227-34.
29. Bluhm G, Nordlander R, Ransjo U. Antibiotic prophylaxis in pacemaker surgery: a prospective double blind trial with systemic administration of antibiotic versus placebo at implantation of cardiac pacemakers. Pacing Clin Electrophysiol 1986;9: 720-6.
30. de Oliveira JC, Martinelli M, Nishioka SA, Varejao T, Uipe D, Pedrosa AA et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, doubleblinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:29-34.
31. Glieca F, Luciani N, Di GiammarcoG, RomoloM, Falcone F, Di Nardo E et al. The role of antibiotic prophylaxis in the implantation of pacemakers. Minerva Cardioangiol 1987;35:549-52.
32. Luninghake F, Gottschalk A, Stierle U, Potratz J, Sack K, Diederich K. Antibiotic prophylaxis for pacemaker implantation: a prospective randomized trial in 302 patients. Pacing Clin Electrophysiol 1993;16:1138.
33. Mounsey JP, Griffith MJ, Tynan M, Gould FK, MacDermott AF, Gold RG et al. Antibiotic prophylaxis in permanent pacemaker implantation: a prospective randomised trial. Br Heart J 1994;72:339-43.
34. Muers MF, Arnold AG, Sleight P. Prophylactic antibiotics for cardiac pacemaker implantation: a prospective trail. Br Heart J 1981;46:539-44.
35. Ramsdale DR, Charles RG, Rowlands DB, Singh SS, Gautam PC, Faragher EB. Antibiotic prophylaxis for pacemaker implantation: a prospective randomized trial. Pacing Clin Electrophysiol 1984;7:844-9.
36. Aggarwal RK, Connelly DT, Ray SG, Ball J, Charles RG. Early complications of permanent pacemaker implantation: no difference between dual and single chamber systems. Br Heart J 1995;73:571-5.
37. Bertaglia E, Zerbo F, Zardo S, Barzan D, Zoppo F, Pascotto P. Antibiotic prophylaxis with a single dose of cefazolin during pacemaker implantation: incidence of longterm infective complications. Pacing Clin Electrophysiol 2006;29:29-33.
38. Bru P, Cointe R, Metge M, MalletMN, Moyal C, Dolla E et al. Value of systematic preventive antibiotherapy in cardiac pacemaker implantation. Ann Cardiol Angeiol (Paris) 1991;40:171-4.
39. Chauhan A, Grace AA, Newell SA, Stone DL, Shapiro LM, Schofield PM et al. Early complications after dual chamber versus single chamber pacemaker implantation. Pacing Clin Electrophysiol 1994;17:2012-5.
40. Klug D, Balde M, Pavin D, Hidden-Lucet F, Clementy J, Sadoul N et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007;116:1349-55.
41. Krahn AD, Lee DS, Birnie D, Healey JS, Crystal E, Dorian P et al. Predictors of shortterm complications after implantable cardioverter-defibrillator replacement: results from the Ontario ICD Database. Circ Arrhythm Electrophysiol 2011;4:136-42.
42. Kron J. Clinical significance of device-related complications in clinical trials and implications for future trials: insights from the Antiarrhytmics Versus Implantable Defibrillators (AVID) trial. Card Electrophysiol Rev 2003;7:473-8.
43. Landolina M, Gasparini M, Lunati M, Iacopino S, Boriani G, Bonanno C et al. Longterm complications related to biventricular defibrillator implantation: rate of surgical revisions and impact on survival: insights from the Italian Clinical Service Database. Circulation 2011;123:2526-35.
44. MacFadden DR, Crystal E, Krahn AD, Mangat I, Healey JS, Dorian P et al. Sex differences in implantable cardioverter-defibrillator outcomes: findings from a prospective defibrillator database. Ann Intern Med 2012;156:195-203.
45. Metais M, Hebrard A, Duparc A, Mondoly P, Delay M, Lepage B et al. Cardiac implantable devices: surveillance of surgical site infections and assessment of professional practices. Arch Cardiovasc Dis 2011;104:325-31.
46. Mueller X, Sadeghi H, Kappenberger L. Complications after single versus dual chamber pacemaker implantation. Pacing Clin Electrophysiol 1990;13:711-4.
47. Romeyer-Bouchard C, Da Costa A, Dauphinot V, Messier M, Bisch L, Samuel B et al. Prevalence and risk factors related to infections of cardiac resynchronization therapy devices. Eur Heart J 2010;31:203-10.
48. Uslan DZ, Gleva MJ,Warren DK, Mela T, Chung MK, Gottipaty V et al. Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE Registry. Pacing Clin Electrophysiol 2012;35:81-7.
49. Gould PA, Gula LJ, Champagne J, Healey JS, Cameron D, Simpson C et al. Outcome of advisory implantable cardioverter-defibrillator replacement: one-year follow-up. Heart Rhythm 2008;5:1675-81.
50. Herce B, Nazeyrollas P, Lesaffre F, Sandras R, Chabert JP, Martin A et al. Risk factors for infection of implantable cardiac devices: data from a registry of 2496 patients. Europace 2013;15:66-70.
51. Lekkerkerker JC, van Nieuwkoop C, Trines SA, van der Bom JG, Bernards A, van de Velde ET et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart 2009;95:715-20.
52. Marschall J, Hopkins-Broyles D, Jones M, Fraser VJ,Warren DK. Case-control study of surgical site infections associated with pacemakers and implantable cardioverterdefibrillators. Infect Control Hosp Epidemiol 2007;28:1299-304.
53. Nery PB, Fernandes R, Nair GM, Sumner GL, Ribas CS, Menon SM et al. Device-related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences. J Cardiovasc Electrophysiol 2010;21: 786-90.
54. Raad D, Irani J, Akl EG, Choueiri S, Azar E, Abboud J et al. Implantable electrophysiologic cardiac device infections: a risk factor analysis. Eur J Clin Microbiol Infect Dis 2012; 31:3015-21.
55. Al-Khatib SM, Lucas FL, Jollis JG, Malenka DJ,Wennberg DE. The relation between patients outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. J AmColl Cardiol 2005; 46:1536-40.
56. Armaganijan LV, Toff WD, Nielsen JC, Andersen HR, Connolly SJ, Ellenbogen KA et al. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol 2012;35: 131-4.
57. Bloom HL, Constantin L, Dan D, De Lurgio DB, El-Chami M, Ganz LI et al. Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope. Pacing Clin Electrophysiol 2011;34:133-42.
58. Borleffs CJ, Thijssen J, de Bie MK, van Rees JB, vanWelsenes GH, van Erven L et al. Recurrent implantable cardioverter-defibrillator replacement is associated with an increasing risk of pocket-related complications. Pacing Clin Electrophysiol 2010; 33:1013-9.
59. Catanchin A, Murdock CJ, Athan E. Pacemaker infections: a 10-year experience. Heart Lung Circ 2007;16:434-9.
60. Cengiz M, Okutucu S, Ascioglu S, Sahin A, Aksoy H, Sinan DeveciOet al. Permanent pacemaker and implantable cardioverter defibrillator infections: seven years of diagnostic and therapeutic experience of a single center. Clin Cardiol 2010;33:406-11.
61. Charytan DM, Patrick AR, Liu J, Setoguchi S, Herzog CA, BrookhartMAet al. Trends in the use and outcomes of implantable cardioverter-defibrillators in patients undergoing dialysis in the United States. Am J Kidney Dis 2011;58:409-17.
62. Dasgupta A, Montalvo J, Medendorp S, Lloyd-Jones DM, Ghossein C, Goldberger J et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. Am J Kidney Dis 2007;49:656-63.
63. Gil P, Fernandez Guerrero ML, Bayona JF, Rubio JM, de Gorgolas M, Granizo JJ et al. Infections of implantable cardioverter-defibrillators: frequency, predisposing factors and clinical significance. Clin Microbiol Infect 2006;12:533-7.
64. Harcombe AA, Newell SA, Ludman PF, Wistow TE, Sharples LD, Schofield PM et al. Late complications following permanent pacemaker implantation or elective unit replacement. Heart 1998;80:240-4.
65. Hartstein AI, Jackson J, Gilbert DN. Prophylactic antibiotics and the insertion of permanent transvenous cardiac pacemakers. J Thorac Cardiovasc Surg 1978;75: 219-23.
66. Higgins SL, Pak JP, Barone J, Williams SK, Bollinger FM, Whiting SL et al. The first year experience with the dual chamber ICD. Pacing Clin Electrophysiol 2000;23:18-25.
67. Johansen JB, Jorgensen OD, MollerM, Arnsbo P, Mortensen PT, Nielsen JC. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J 2011;32:991-8.
68. Kiviniemi MS, Pirnes MA, Eranen HJ, Kettunen RV, Hartikainen JE. Complications related to permanent pacemaker therapy. Pacing Clin Electrophysiol 1999;22:711-20.
69. Mela T, McGovern BA, Garan H, Vlahakes GJ, TorchianaDF, Ruskin J et al. Long-term infection rates associated with the pectoral versus abdominal approach to cardioverter- defibrillator implants. Am J Cardiol 2001;88:750-3.
70. Mugica J, Brichler J. Value of systematic antibiotic therapy after implantation of a pacemaker. Study of 2,016 cases. Nouv Presse Med 1977;6:733-4.
71. Pakarinen S, Oikarinen L, Toivonen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. Europace 2010;12:103-8.
72. Rao G, Ford WB, Zikria EA, Miller WH, Samadani SR. Incidence and prevention of infection in patients with permanent cardiac pacemakers. Int Surg 1974;59:559-61.
73. Schuchert A, Muto C, Maounis T, Frank R, Boulogne E, Polauck A et al. Lead complications, device infections, and clinical outcomes in the first year after implantation of cardiac resynchronization therapy-defibrillator and cardiac resynchronization therapy-pacemaker. Europace 2013;15:71-6.
74. Smith PN, Vidaillet HJ, Hayes JJ,Wethington PJ, Stahl L, Hull M et al. Infections with nonthoracotomy implantable cardioverter defibrillators: can these be prevented? Endotak Lead Clinical Investigators. Pacing Clin Electrophysiol 1998;21:42-55.
75. Tompkins C, McLean R, Cheng A, Brinker JA, Marine JE, Nazarian S et al. End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol 2011;22:1099-104.
76. Trappe HJ, Pfitzner P, Klein H,Wenzlaff P. Infections after cardioverter-defibrillator implantation: observations in 335 patients over 10 years. Br Heart J 1995;73:20-4.
77. Wunderly D, Maloney J, Edel T, McHenry M, McCarthy PM. Infections in implantable cardioverter defibrillator patients. Pacing Clin Electrophysiol 1990;13:1360-4.
78. Ito I, Kono K, Shinbo G, Tadokoro K, Abe C, Takemura N et al. Implantable cardioverter defibrillator in maintenance hemodialysis patients with ventricular tachyarrhythmias: a single-center experience. Hemodial Int 2009;13:48-54.
79. Palmisano P, Accogli M, Zaccaria M, Luzzi G, Nacci F, AnaclerioMet al. Rate, causes, and impact on patient outcome of implantable device complications requiring surgical revision: large population survey from two centres in Italy. Europace 2013;15: 531-40.
80. Peterson PN, Varosy PD, Heidenreich PA,Wang Y, Dewland TA, Curtis JP et al. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA 2013;309: 2025-34.
81. Lyman S, Sedrakyan A, Do H, Razzano R, Mushlin AI. Infrequent physician use of implantable cardioverter-defibrillators risks patient safety. Heart 2011;97:1655-60.
82. Daubert JC, Saxon L, Adamson PB, Auricchio A, Berger RD, Beshai JF et al. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace 2012;14:1236-86.
83. Swindle JP, Rich MW, McCann P, Burroughs TE, Hauptman PJ. Implantable cardiac device procedures in older patients: use and in-hospital outcomes. Arch Intern Med 2010;170:631-7.
84. Kolek MJ, Dresen WF,Wells QS, Ellis CR. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol 2013;36:354-61.
85. Mittal S, Shaw RE, Michel K, Palekar R, Arshad A, Musat D et al. Cardiac implantable electronic device infections: incidence, risk factors, and the effect of the AigisRx antibacterial envelope. Heart Rhythm 2014;11:595-601.
86. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e326S-350S.
87. Birnie DH, Healey JS,Wells GA, Verma A, Tang AS, Krahn AD et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368:2084-93.
88. Amin MS, Matchar DB,Wood MA, Ellenbogen KA. Management of recalled pacemakers and implantable cardioverter-defibrillators: a decision analysis model. JAMA 2006;296:412-20.
89. Uslan DZ, Dowsley TF, Sohail MR, Hayes DL, Friedman PA, Wilson WR et al. Cardiovascular implantable electronic device infection in patients with Staphylococcus aureus bacteremia. Pacing Clin Electrophysiol 2010;33:407-13.
90. Obeid KM, Szpunar S, Khatib R. Long-term outcomes of cardiovascular implantable electronic devices in patients with Staphylococcus aureus bacteremia. Pacing Clin Electrophysiol 2012;35:961-5.
91. Bongiorni MG, Tascini C, Tagliaferri E, Di Cori A, Soldati E, Leonildi A et al. Microbiology of cardiac implantable electronic device infections. Europace 2012;14: 1334-9.